AZD7648 / AstraZeneca - LARVOL DELTA

DISSECTING THE HELLS GENE SIGNATURE IN ANAPLASTIC LARGE CELL LYMPHOMA: IMPLICATIONS FOR DRUG REPURPOSING AND COMBINATION THERAPY (EHA 2025) - "To validate these results, we treated HELLSKD and control cells with IC20 dose of a representative compound of each class (BKM-120 for PI3K, Ruxolitinib for JAK1/2, AZD7648 for DNA-PK). Collectively, these findings pave the way for the development of effective and clinically translatable strategies for HELLS inhibition. Such pharmacological inhibitors hold promise not only as monotherapy but also in synergistic combination with conventional and targeted therapies"

Combination therapy • Gene Signature • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • ALK • HELLS • IFNG • JAK1 • JAK2

Application of Biological Modifiers to a Multiplexed, Human Cell-Based DNA Damage Assay Provides Mechanistic Information on Genotoxicity and Molecular Targets. (PubMed, Environ Mol Mutagen) - "Cells were exposed in 96-well plates in the presence and absence of each of four modifying agents at one optimized concentration: talazoparib (PARP inhibitor), MK-8776 (CHK1 inhibitor), AZD-7648 (DNA-PK inhibitor), or a cocktail of reactive oxygen species scavengers. Unsupervised hierarchical clustering of the collective potency metrics for various combinations of biomarkers showed that clastogens with similar genotoxic mechanisms grouped together. Overall, this study shows that in combination with biological response modifiers, MultiFlow and In Vitro MicroFlow biomarkers can provide mechanistic insights into chemical-induced genotoxicity."

Journal

A hybrid gene correction strategy for Cystic Fibrosis (ASGCT 2025) - "The correction efficiency could be further enhanced by using AZD7648, an inhibitor of DNA-PK, achieving up to 81% corrected alleles. We are now validating this therapeutic approach in more advanced models such as precision-cut human lung slices. Disease Focus of Abstract:Cystic Fibrosis"

Cystic Fibrosis • Genetic Disorders • Immunology • Respiratory Diseases • CFTR

Genome editing with AZD7648 induces large-scale genomic alterations (ASGCT 2025) - "We found that genome editing with AZD7648 causes frequent kilobase-scale and megabase-scale deletions, chromosome arm loss and translocations. These large-scale chromosomal alterations evade detection through typical genome editing assays, prompting caution in deploying AZD7648 and reinforcing the need to investigate multiple types of potential editing outcomes."

Site-Specific Gene Integration Strategies for IL7Rα-SCID Hematopoietic Stem Cell Gene Therapy (ASGCT 2025) - "We tackled this issue by adding AZD7648, a potent DNA-PK inhibitor, to influence DNA repair further towards the HDR pathway while adding lower amounts of the donor template...Crucially, we are also looking into sequence fidelity of the integrated transgenes due to reports of IL7Rα gain-of-function mutations in Leukemia patients. Disease Focus of Abstract:Immunodeficiency"

Gene therapy • Gene Therapies • Hematological Malignancies • Immunology • Leukemia • Oncology • Primary Immunodeficiency • CD34 • IL7 • IL7R

OVERCOMING CHEMOTHERAPY RESISTANCE THROUGH TARGETED INHIBITION OF DNA-PK-DEPENDENT DNA REPAIR. (EHA 2025) - "High-throughput drug screening, Synergism scoring, Western blot, Cell cycle with yH2AX analysis, Apoptosis assay with AnnexinV, in vivo experiment with AML Patient-derived Xenograft(PDX) mouse model.High-throughput drug response testing of the DNA-PKi AZD7648 and chemotherapy alone and in combination demonstrated that inhibition of DNA-PK synergistically enhanced chemotherapy response across seven AML cell lines (TP53mut/del, n=5; TP53wt, n=2) and TP53mut/del AML patient samples (n=3)... Combinatorial treatment with chemotherapy and a DNA-PK inhibitor synergistically inhibited growth and survival of AML cells in vitro and significantly prolonged survival of mice with AML compared to untreated or single-treated mice. Our findings highlight the potential of DNA-PKi to improve response and overcome chemotherapy resistance in both TP53wt and TP53mut/del AML patients.Reference:PMID: 35797463PMID: PMC2754209PMID:33299144"

IO biomarker • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology • ANXA5 • BCL2 • MCL1

The DNA-PK inhibitor AZD7648 alone or combined with pegylated liposomal doxorubicin in patients with advanced cancer: results of a first-in-human Phase I/IIa study. (PubMed, Br J Cancer) - P1/2 | "Toxicity of AZD7648 + PLD was greater than expected and antitumour activity was limited, leading to early study termination."

Journal • P1/2 data • Gastroenterology • Gastrointestinal Disorder • Hematological Disorders • Oncology

The DNA-PK inhibitor AZD7648 alone or combined with pegylated liposomal doxorubicin in patients with advanced cancer: results of a first-in-human Phase I/IIa study (Nature, Br J Cancer) - P1/2a | N=30 | NCT03907969 | Sponsor: AstraZeneca | "AZD7648 monotherapy was administered at 5–160 mg BID. The most frequent class of adverse events was gastrointestinal disorders (9/14 patients, 64.3%); one patient (160 mg BID) experienced dose-limiting toxicities (DLTs). No responses to AZD7648 monotherapy were observed. The maximum dose of combination therapy was AZD7648 40 mg QD days 1–7 + PLD every 28 days. 13/16 patients (81.3%) experienced gastrointestinal disorders and 11/16 (68.8%) patients had anaemia. Three patients experienced DLTs (two at AZD7648 20 mg QD 7 days + PLD; one at AZD7648 30 mg QD 7 days + PLD). Limited efficacy was observed, with one RECIST partial response."

P1/2 data • Solid Tumor

The DNA-PK inhibitor AZD7648 alone or combined with pegylated liposomal doxorubicin in patients with advanced cancer: results of a first-in-human Phase I/IIa study (Nature, Br J Cancer) - P1/2a | N=30 | NCT03907969 | Sponsor: AstraZeneca | "AZD7648 monotherapy was administered at 5–160 mg BID. The most frequent class of adverse events was gastrointestinal disorders (9/14 patients, 64.3%); one patient (160 mg BID) experienced dose-limiting toxicities (DLTs). No responses to AZD7648 monotherapy were observed. The maximum dose of combination therapy was AZD7648 40 mg QD days 1–7 + PLD every 28 days. 13/16 patients (81.3%) experienced gastrointestinal disorders and 11/16 (68.8%) patients had anaemia. Three patients experienced DLTs (two at AZD7648 20 mg QD 7 days + PLD; one at AZD7648 30 mg QD 7 days + PLD). Limited efficacy was observed, with one RECIST partial response."

P1/2 data • Solid Tumor

N-(5-(2-morpholino-4-oxo-3,4-dihydroquinazolin-8-yl)pyridin-2-yl)acylamides as novel multi-PI3K/DNA-PK/P-gp inhibitors for efficient chemosensitization and MDR alleviation. (PubMed, Eur J Med Chem) - "Compared to a commercial DNA-PK/PI3K inhibitor AZD7648, synthesized compounds generally exhibited markedly lower baseline cytotoxicity in all tested cell lines (MC38, B16F10, 4T1, CT26 and HEK-239)...While in cell-free conditions, 6 acted as a very efficient pan-PI3K and DNA-PK inhibitor, in physiological conditions, 2 performed better and acted as a potent chemosensitizer able to increase the amount of DNA double strand breaks induced by doxorubicin...We also demonstrate that 2 can be simply loaded into lipid nanoparticles that retain its chemosensitizing properties. Taken together, the presented study provides a solid basis for a subsequent rational structure optimization towards new generation of multitarget inhibitors able to control crucial signaling pathways involved in tumorigenesis and drug resistance."

Journal • Oncology • ABCC1

Early biomarker dynamics are associated with treatment efficacy in a preclinical model of radiotherapy combined with a DNA damage response agent (AACR 2025) - "In summary, both in vitro assays and in vivo models have been developed to explore the synergistic effects of combining radiotherapy with DDR agents. The combination of radiotherapy with the AZD7648 inhibitor resulted in delayed tumor growth in vivo. Early changes in protein and gene biomarkers were consistent with target engagement and treatment efficacy."

Preclinical • Lung Cancer • Oncology • Solid Tumor

AZD7648 (DNA-PKcs inhibitor): a two-edged sword for editing genomes. (PubMed, Funct Integr Genomics) - "published in Nature Biotechnology showed interesting features of AZD7648 (a DNA-PKcs inhibitor) that increase the probability of HDR event while DNA repairing (Cullot et al. 2024)."

Journal

DNA-PK inhibition enhances gene editing efficiency in HSPCs for CRISPR-based treatment of X-linked hyper IgM syndrome. (PubMed, Mol Ther Methods Clin Dev) - "Our combined findings demonstrate HDR editing at the CD40LG locus at potentially clinically beneficial levels. More broadly, these data support using DNA-PKcs inhibition with AZD7648 as a simple and efficacious addition to HSPC editing platforms."

Journal • Immunology • Primary Immunodeficiency • Transplantation • CD34 • CD40LG

Defining preclinical efficacy with the DNAPK inhibitor AZD7648 in combination with olaparib: a minimal systems pharmacokinetic-pharmacodynamic model. (PubMed, J Pharmacokinet Pharmacodyn) - "Furthermore, the model can be utilized to assess what exposures would be necessary in the clinic by linking it to observed or predicted human PK exposures. The model suggests 64.9 uM olaparib is sufficient to achieve tumor stasis in the absence of AZD7648, while the combination of AZD7648 and olaparib only requires plasma concentrations of 20.2 uM AZD7648 and 19.9 uM olaparib at steady-state to achieve the same effect."

Journal • PK/PD data • Preclinical • Oncology

Enhanced fetal hemoglobin production via dual-beneficial mutation editing of the HBG promoter in hematopoietic stem and progenitor cells for β-hemoglobinopathies. (PubMed, Stem Cell Res Ther) - "Cas9 RNP-ssODN-based nucleotide conversion at the HBG promoter offers a promising gene therapy approach to ameliorate the phenotypes of β-thalassemia and SCD. The developed approach can simplify and broaden applications that require the cointroduction of multiple nucleotide modifications in HSPCs."

Journal • Beta-Thalassemia • Gene Therapies • Genetic Disorders • Hematological Disorders • Sickle Cell Disease

Enhanced radiosensitivity of head and neck cancer cells to proton therapy via hyperthermia-induced homologous recombination deficiency. (PubMed, Clin Transl Radiat Oncol) - "In this study, we examined the response of FaDu cells, a head and neck squamous cell carcinoma model, to spread-out Bragg peak (SOBP) proton and photon radiation combined with mild hyperthermia (42 °C for one hour) to induce homologous recombination deficiency or NHEJ inhibition by AZD7648...These findings support the hypothesis that cells rely more on homologous recombination to repair proton-induced DNA damage compared to photon-induced DNA damage. As clinically applied hyperthermia enhances the therapeutic effect of photon irradiation by, among other factors, inducing homologous recombination deficiency, our results suggests that hyperthermia could be more effective in combination with proton irradiation than photon irradiation."

Journal • Head and Neck Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • HRD • RAD51

BCCA7693 - A novel, orally bioavailable DNA-PK inhibitor demonstrates efficacy with targeted MAPK and PARP therapeutics by slowing the development of acquired resistance (EORTC-NCI-AACR 2024) - "Biochemical and cellular screening assays were used to identify compounds having high potency, selectivity and desirable ADME characteristics, comparable to those recently evaluated by clinical trials in combinations with DNA-damaging anti-cancer treatments including radiotherapy (AZD7648 and M3814)...In recent in vitro and in vivo studies, BCCA7693 has also demonstrated efficacy with targeted therapeutics, decreasing tumour cell survival during replicative stress and thereby blocking the development of acquired resistance induced by a variety of MAPK, RTK and PARP inhibitors (Trametinib, Adagrasib, Dabrafenib, Afatinib and Olaparib). Crucially, in contrast to radio- and chemotherapy, murine studies with BCCA7693 did not result in increased toxicity for combination treatments with molecular targeted therapeutics, suggesting the potential for an additional clinical application of this DSB repair inhibitor. In Conclusion, BCCA7693, shows potential for combination with a..."

Clinical • Late-breaking abstract • Preclinical • Oncology • PARP1

Genome editing with the HDR-enhancing DNA-PKcs inhibitor AZD7648 causes large-scale genomic alterations. (PubMed, Nat Biotechnol) - "We found that genome editing with AZD7648 causes frequent kilobase-scale and megabase-scale deletions, chromosome arm loss and translocations. These large-scale chromosomal alterations evade detection through typical genome editing assays, prompting caution in deploying AZD7648 and reinforcing the need to investigate multiple types of potential editing outcomes."

Journal

DNA-PKcs inhibition improves sequential gene insertion of the full-length CFTR cDNA in airway stem cells. (PubMed, Mol Ther Nucleic Acids) - "To improve CFTR cDNA insertion in human airway basal stem cells (ABCs), we evaluated the use of the small molecules AZD7648 and ART558, which inhibit non-homologous end-joining (NHEJ) and micro-homology mediated end-joining (MMEJ). Adding AZD7648 did not increase off-target editing. Further studies are necessary to validate if AZD7648 treatment enriches cells with oncogenic mutations."

Journal • Cystic Fibrosis • Genetic Disorders • Immunology • Oncology • Pulmonary Disease • Respiratory Diseases • CFTR

DNA-PKcs Inhibition Improves Sequential Gene Insertion of the Full-Length CFTR cDNA in Airway Stem Cells. (PubMed, bioRxiv) - "To improve CFTR cDNA insertion in human airway basal stem cells (ABCs), we evaluated the use of the small molecules AZD7648 and ART558 which inhibit non-homologous end joining (NHEJ) and micro-homology mediated end joining (MMEJ). Adding AZD7648 did not increase off-target editing. Further studies are necessary to validate if AZD7648 treatment enriches cells with oncogenic mutations."

Journal • Cystic Fibrosis • Genetic Disorders • Immunology • Oncology • Pulmonary Disease • Respiratory Diseases • CFTR

PRKDC Induces Chemoresistance in Osteosarcoma by Recruiting GDE2 to Stabilize GNAS and Activate AKT. (PubMed, Cancer Res) - "Using a kinome-wide CRISPR screen, we identified PRKDC as a critical determinant of doxorubicin (DOX) sensitivity in osteosarcoma. The PRKDC inhibitor AZD7648 and DOX synergized and strongly suppressed the growth of osteosarcoma in mouse xenograft models and human organoids. In conclusion, the PRKDC-GDE2-GNAS-AKT regulatory axis suppresses DOX sensitivity and comprises targetable candidates for improving the efficacy of chemotherapy in osteosarcoma."

Journal • Oncology • Osteosarcoma • Sarcoma • Solid Tumor • GNAS • PRKDC

DNA-PKcs Inhibition Sensitizes Human Chondrosarcoma Cells to Carbon Ion Irradiation via Cell Cycle Arrest and Telomere Capping Disruption. (PubMed, Int J Mol Sci) - "A time-dependent shortening of telomere length was observed in both cell lines after combined treatment with AZD7648 and 8 Gy X-ray/C-ion IR. Our data suggest that the inhibition of DNA-PKcs may increase sensitivity to X-rays and C-ion IR by impairing its functional role in DNA repair mechanisms and telomere end protection."

Journal • Oncology • Sarcoma • Solid Tumor • CDK1 • CHEK2

Effective Radiosensitization of HNSCC Cell Lines by DNA-PKcs Inhibitor AZD7648 and PARP Inhibitors Talazoparib and Niraparib. (PubMed, Int J Mol Sci) - "Healthy fibroblasts tolerated AZD7648 alone extremely well, but irradiation-induced effects might occur. Our results justify in vivo studies."

Journal • Preclinical • Head and Neck Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • ANXA5

Stimulating macropinocytosis of peptide-drug conjugates through DNA-dependent protein kinase inhibition for treating KRAS-mutant cancer. (PubMed, J Control Release) - "AZD7648 possesses broad applications in augmenting nano-sized drug delivery and preventing DNA repair resistance. The promising efficacy and evident synergy underscore the potential of combining MPD1 with AZD7648 as a strategy for treating KRAS-mutant cancers."

Journal • Oncology • CASP3 • KRAS

Inhibition of key DNA double strand break repair protein kinases enhances radiosensitivity of head and neck cancer cells to X-ray and proton irradiation. (PubMed, Cell Death Discov) - "Using inhibitors targeting ATM (AZD1390), ATR (AZD6738) and DNA-Pkcs (AZD7648), we observed that this led to significantly decreased clonogenic survival of HNSCC cell lines following both X-ray and proton irradiation. We confirmed that the inhibitors in combination with X-rays and protons led to DSB persistence, and increased micronuclei formation. Cumulatively, our data suggest that targeting DSB repair, particularly via ATM and DNA-Pkcs inhibition, can exacerbate the impact of ionising radiation in sensitising HNSCC cell models."

Journal • Ataxia • Head and Neck Cancer • Immunology • Movement Disorders • Oncology • Primary Immunodeficiency • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • ATR